GeoVax's Next-Gen Single Dose COVID-19 Vaccine Shows Promising Results

GeoVax Labs Inc GOVX announced the presentation of updates on developing its next-generation COVID-19 vaccine, GEO-CM04S1, including preliminary data from an ongoing Phase 2 trial.
The data were presented at the Vaccines Summit Boston 2023 and the Congress for the International Society for the Advancement of Cytometry 2023 meetings.
The preliminary analysis indicated CM04S1 is highly immunogenic, inducing both antibody responses, including neutralizing antibodies and T cell responses.
These data support the planned progression of the Phase 2 study, which includes a direct comparison to currently approved mRNA vaccines.
CM04S1 continues to advance in a second Phase 2 trial as a booster for healthy patients who have previously received the Pfizer Inc PFE or Moderna Inc MRNA mRNA vaccine.
Data from these studies will form the basis for comparing vaccine potential in unique patient groups and the general population.
CM04S1 is a next-generation COVID-19 vaccine based on GeoVax's MVA viral vector platform, which supports the presentation of multiple vaccine antigens to the immune system in a single dose.
CM04S1 presents both the spike and nucleocapsid antigens of SARS-CoV-2 and is specifically designed to induce antibody and T-cell responses to non-variable parts of the virus.
Based on data from animal models and a completed Phase 1 study, vaccine-induced immune responses were shown to recognize both early and later variants, including the Omicron variant.
Vaccines of this format should not require repeated modification and updating.
Price Action: GOVX shares are up 4.22% at $0.69 on the last check Wednesday.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga